Markets:

Overview

News

Currencies

International

Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.230 +0.170 (+4.19%)

Streaming Delayed Price Updated: 1:41 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research

March 14, 2023

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update

March 02, 2023

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update

February 16, 2023

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Biopharma's Return On Capital Employed Insights ↗

December 12, 2022

Via Benzinga

Recap: Arbutus Biopharma Q2 Earnings ↗

August 04, 2022

Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Arbutus Biopharma: Q1 Earnings Insights ↗

May 05, 2022

Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Arbutus to Participate in Three Upcoming Investor Conferences

February 06, 2023

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Announces Resignation of Board Member

January 27, 2023

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Announces 2023 Corporate Objectives and Provides Financial Update

January 05, 2023

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

December 13, 2022

From Arbutus Biopharma Corporation

Via GlobeNewswire

Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims ↗

December 06, 2022

Via Benzinga

Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 09, 2022

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus to Present at Jefferies London Healthcare Conference

November 08, 2022

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®

November 01, 2022

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022

October 31, 2022

From Arbutus Biopharma Corporation

Via GlobeNewswire

Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update

October 26, 2022

From Arbutus Biopharma Corporation

Via GlobeNewswire

Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End

September 30, 2022

From Arbutus Biopharma Corporation

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

September 13, 2022

Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares!

Via InvestorPlace

Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know ↗

August 26, 2022

Moderna Inc (NASDAQ: MRNA) has

Via Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners ↗

July 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗

July 06, 2022

The company isn't seeking an injunction, but wants "fair compensation."

Via Investor's Business Daily

Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗

July 05, 2022

The company isn't seeking an injunction, but wants "fair compensation."

Via Investor's Business Daily

This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B ↗

June 28, 2022

Via Benzinga

Morning Brief: Top Financial Stories Dominating on Monday, May 9 ↗

May 09, 2022

CNBC Ford Motor Selling 8M Shares Of Rivian Automotive

Via Benzinga

Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ ↗

May 09, 2022

Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking...

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Arbutus Biopharma Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 28, 2022

Arbutus Biopharma (NASDAQ:ABUS) will host a conference call at 08:45 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters ↗

March 18, 2022

Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,

Via Benzinga

Arbutus Biopharma Earnings Perspective: Return On Capital Employed ↗

March 09, 2022

Benzinga Pro data, Arbutus Biopharma (NASDAQ:ABUS) reported Q4 sales of $3.21 million. Earnings fell to a loss of $21.32 million, resulting in a 11.29% decrease from last quarter...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.